Supplementary Table 1. Previous publications on HBV-positive donors to HBV-negative recipients

Year	Study	Country	Donor type	D+R– group details	D–R– group details	Outcomes	Results	Prophylaxis protocol	Follow-up duration
2009	Jiang et al. [12]	China	Deceased donor	Recipient HBsAb+ (n = 65)	Recipient HBsAb+ (n = 308)	OS (KM)	p = 0.294	HBIG/lamivudine 100 mg daily for 6 mo	38.7 ± 15.4 mo (range, 6–71 mo)
						GS (KM)	p = 0.639		
						HBV infection	1/65 vs. 1/308, p = 0.319		
						Acute rejection	6/65 vs. 35/308, p = 0.827		
						Liver injury	39/65 vs. 207/308, p = 0.313		
2012	Tuncer et al. [13]	Turkey (Medical Park Hospital Transplantation Center)	Living donor	Recipient HBsAb+ (n = 35)	(n = 1,195)	OS	0/35 vs. 34/1,195, p = 0.621	No HBIG/no lamivudine	Not report
						GS	1/35 vs. 55/1,195, p > 0.999		
						Rejection	7/35 vs. 232/1,195, p > 0.999		
						eGFR	No difference at both 1 and 2 year		
						Liver function	No difference at both 1 and 2 year		
2014	Chancharoenthana et al. [14]	Thailan)	Living and deceased donor	Recipient HBsAb >100 (n = 43)	Recipient HBsAb >100 (n = 86)	OS (KM)	p = 0.50	Lamivudine 100 mg daily for 12 mo	Median 58.2 mo (range, 16.7–158.3 mo)
						GS (KM)	p = 0.43		
						HBV infection	0/43 vs. 0/86		
2015	Asuman et al. [15]	Turkey (Medical Park Hospital Transplantation Center)	Living donor	Recipient HBsAb+ (n = 111)	(n = 2,168)	OS	6/111 vs. 102/2,168, p = 0.648	No HBIG/no lamivudine	Not report
						GS	4/111 vs. 123/2,168, p = 0.522		
						Acute rejection	26/111 vs. 375/2,168, p = 0.124		
						HBV infection	0/111 vs. 0/2,168		
2015	Yilmaz et al. [16]	Turkey	Living and deceased donor	Most recipient HBsAb+ (not clearly declared) (n = 26)	Most recipient HBsAb+ (not clearly declared) (n = 52)	OS	1/26 vs. 0/52, p = 0.333	Lamivudine 100 mg daily for 6 mo	Not report
						GS	3/26 vs. 9/52, p = 0.741		
						DGF	1/26 vs. 3/52, p > 0.999		
						Acute rejection	7/26 vs. 16/52, p = 0.797		
						Acute HBV infection	3/26 vs. 0/52, p = 0.034		
						eGFR	No difference		
						ALT	No difference		
2021	Wang et al. [17]	China	Living donor	HBsAb+/– (n = 83)	HBsAb+/– (n = 384)	OS	5/83 vs. 4/384, p = 0.011	HBIG and/or NAs (lamivudine 100 mg daily/entecavir 0.5 mg daily for 1–3 mo)	Median 36 mo
						GS	4/83 vs. 19/384, p > 0.999		
						DGF	2/83 vs. 4/384, p = 0.290		
						Rejection	12/83 vs. 51/384, p = 0.727		
						HBV infection	2/83 vs. 1/384, p = 0.083		
						Infection	34/83 vs. 121/384, p = 0.123		
						Acute liver injury	8/83 vs. 43/384, p = 0.846		
						Liver function abnormal	29/83 vs. 154/384, p = 0.457		
2021	Yuan et al. [18]	United States	Deceased donor	HBsAb not reported	HBsAb not reported	OS (KM)	p = 0.66	Not reported	Not report
				144	144	GS (KM)	p = 0.65		
				144	178374	DGF	26/144 (18.1%) vs. 47,934/178,374 (26.9%), p = 0.018		

(Continued to the next page)

Supplementary Table 1. Continued

Year	Study	Country	Donor type	D+R– group details	D–R– group details	Outcomes	Results	Prophylaxis protocol	Follow-up duration
2021	Delman et al. [19]	United States	Deceased donor	Recipient HBsAb+/– (n = 56)	Recipient HBsAb+/– (n = 308)	OS (KM)	p = 0.94	0.5 mg entecavir every day for 1 year regardless of HBsAb status	Median 1 yr
						GS (KM)	p = 0.26		
						HBV infection episodes	0/56		
2024	Current study		Deceased donor	Recipient HBsAb+/– (n = 94)	Recipient HBsAb+/– (n = 649)	OS	HR, 0.39, p = 0.11 (4/94 vs. 42/649)	HBIG with or without lifelong entecavir	Median 34 mo (IQR, 16–52 mo)
						DCGS	HR, 0.86, p = 0.70 (10/94 vs. 65/649)		
						DGF	OR, 0.763, p = 0.613 (17/94 vs. 116/649)		
						HBV infection	6/72 vs. 3/231, p = 0.007		
						Peak eGFR within 12 mo	β = 1.014, p = 0.709		
						Protective role of HBsAb titer	<10 IU/L (4/15)		
							10–100 IU/L (2/19)		
							>100 IU/L (0/38)		
							p for trend = 0.003		
						Prophylaxis of NAs for HBV infection	1/22 vs. 5/50, p = 0.660		

ALT, serum alanine transaminase; D+R–, donor HBsAg+/recipient HBsAg–; D–R–, donor HBsAg–/recipient HBsAg–; DCGS, death-censored graft survival; DGF, delayed graft function; eGFR, estimated glomerular filtration rate; GS, graft survival; HBIG, hepatitis B immune globulin; HBsAb, hepatitis B surface antibody; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HR, hazard ratio; IQR, interquartile range; KM, Kaplan-Meier survival analysis; NAs, nucleotide analogs; OR, odds ratio; OS, overall survival (patient survival).